{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The assays measure cell viability in PC12/TetOn cells expressing ␣-syn(A30P) and ␣-syn(WT) under doxycycline stimulation. The implication is that the A30P variant affects alpha-synuclein function, leading to cellular dysfunction relevant to Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is inferred through the context of alpha-synuclein dysfunction leading to cell viability changes, a known mechanism in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assays involve cell viability measurements in a model system (PC12/TetOn cells) with doxycycline-induced expression of the variant and wild-type protein.",
          "judgment": "Yes",
          "reasoning": "Cell viability assays in neuronal cell models are standard in the field for assessing the effects of alpha-synuclein variants on cellular health.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The experimental scheme is described as being the same as in (A), and the text states 'three replicates for each condition.' Wild-type (␣-syn(WT)) is used as a control.",
          "judgment": "Yes",
          "reasoning": "Both wild-type (negative control) and variant (␣-syn(A30P)) are used, and the text explicitly states that three replicates were performed.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The wild-type protein (␣-syn(WT)) is used as a control for the A30P variant. However, no other known pathogenic or benign variants are mentioned as controls.",
          "judgment": "No",
          "reasoning": "Only the wild-type protein is used as a control; no other pathogenic or benign variants are referenced.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The text reports statistical significance using one-way ANOVA followed by Tukey's post-hoc test (P < 0.05; **P < 0.01).",
          "judgment": "Yes",
          "reasoning": "The use of ANOVA and post-hoc tests provides a statistical basis for interpreting the functional data.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "No direct OddsPath value is provided in the text. However, the statistical significance (P < 0.01) suggests a strong effect size.",
          "judgment": "Inferred OddsPath > 4.3 based on statistical significance",
          "reasoning": "The significant p-value (P < 0.01) and the comparison to wild-type suggest a moderate to strong OddsPath."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for SNCA p.A30P shows a statistically significant reduction in cell viability compared to wild-type, suggesting a pathogenic effect. The evidence supports PS3_moderate strength."
    }
  ]
}